As previously disclosed, pursuant to Myrexis, Inc.'s Separation and Distribution Agreement with Myriad Genetics, Inc. dated June 30, 2009, at the time of Myrexis' separation from Myriad Genetics, Myrexis assumed liability for certain pending or threatened legal matters related to its business, and is obligated to indemnify Myriad Genetics for any liability arising out of such matters, including any costs and expenses of litigating such matters, including payment of attorneys' fees incurred to defend against claims. One such matter, a lawsuit brought by the Alzheimer's Institute of America, Inc. against Myriad Genetics and Myriad Therapeutics, Inc. and the Mayo Clinic Jacksonville and Mayo Foundation for Medical Education and Research, asserts that Myriad and Mayo infringed certain patents allegedly owned by Alzheimer's Institute of America in connection with Myriad's research and development of its failed Alzheimer's drug candidate Flurizan. Effective December 21, 2012, the parties entered into a settlement agreement that settles fully and finally the Litigation. Pursuant to the terms of the Settlement Agreement, in consideration of Alzheimer's Institute of America's release of claims against and covenant not to sue the other parties for matters related to the Litigation, Myrexis, Inc. has agreed to pay Alzheimer's Institute of America approximately $1,525,000, and transfer to AIA all program rights and assets associated with Myrexis' Hsp90 inhibitor program, cancer metabolism inhibitor program, and small molecule anti-interferon (IKK /TBK1) inhibitor program. Alzheimer's Institute of America will assume Myrexis' liabilities under the program contracts being transferred to Alzheimer's Institute of America and all liabilities for the further conduct of the programs, subject, in each case, to certain exclusions, including liabilities accruing or arising from events occurring prior to the Program Assets Transfer. The Settlement Agreement also includes a release of claims against Alzheimer's Institute of America by each of Myrexis, Myriad and Mayo. Simultaneously with the delivery of the settlement payment to Alzheimer's Institute of America by Myrexis on December 21, 2012, the Parties filed a stipulation of dismissal of the Litigation.

On December 21, 2012, David W. Gryska informed Myrexis of his resignation as Acting President and Chief Executive Officer, Chief Operating Officer and member of the Board of Directors, effective December 24, 2012.